MN HF1117

Establishes comprehensive licensing standards for opioid addiction treatment programs, including requirements for medication orders, minimum drug testing (8 tests per 12 months), and criteria for take-home medication use.

Creates graduated restrictions on methadone take-home doses: single weekly dose in first 90 days, two weekly doses in second 90 days, three weekly doses in third 90 days, six-day supply by end of first year, and maximum two-week supply after one year of continuous treatment.

Requires all chemical dependency treatment programs to provide educational materials about opioid addiction treatment options, including medication-assisted treatment, to clients seeking or identified as having opioid addiction.

Mandates opioid treatment programs to review prescription monitoring program data for all clients at admission and quarterly thereafter to identify multiple prescribers or controlled substance prescriptions, with medical directors required to document findings.

Adds multiple synthetic cannabinoid compounds (including UR-144, XLR-11, AKB-48, PB-22, and 25I-NBOMe) to Schedule I controlled substances list, effective August 1, 2013.